Journal of Diabetes & Metabolic Disorders Pub Date : 2022-07-06 , DOI: 10.1007/s40200-022-01053-9 Motahareh Zeinivand 1 , Nida Jamali-Raeufy 2 , Fahime Zavvari 2
|
Abstract
Coronavirus Disease 2019 (COVID-19) is a recent public health issue worldwide. Also, diabetes is a frequent condition with high mortality. There is a strong relationship between COVID-19 and diabetes. This article analyses the intricate relationship between COVID-19 and hepcidin. Hepcidin increases in aged non-insulin diabetic patients. Hepcidin is the last target treatment of several medications commonly used. Viral diseases, especially SARS-CoV19, can activate the hepcidin pathway leading to an elevation in the iron load. This increased iron is released into the bloodstream and results in cell death through ferroptosis, like free iron. Excess iron has pro-coagulative and toxic effects. Hepcidin overexpression and iron overload are associated with COVID-19 infection and can be considered potential targets for treatment. Several studies have shown dalteparin (anti-Hepcidin) could improve the symptoms of COVID-19 in diabetics by appropriately modulating and decreasing oxidative stress and inflammation. This finding can be leading to enhancing the existing knowledge about Therapeutic measures for reducing Covid-19 impairments in diabetics and is suggested as a possible therapeutic agent in diabetes.
中文翻译：
Hepcidin 肽抑制剂在改善糖尿病患者 COVID-19 症状中的有益作用：抗炎和潜在治疗作用
摘要
2019 年冠状病毒病 (COVID-19) 是全球最近出现的公共卫生问题。此外，糖尿病是一种死亡率很高的常见病症。COVID-19 与糖尿病之间存在密切关系。本文分析了 COVID-19 和铁调素之间错综复杂的关系。老年非胰岛素糖尿病患者的铁调素增加。Hepcidin是目前常用的几种药物的最后一个靶向治疗药物。病毒性疾病，尤其是 SARS-CoV19，可以激活铁调素通路，导致铁负荷升高。这种增加的铁被释放到血液中，并像游离铁一样通过铁死亡导致细胞死亡。过量的铁具有促凝血和毒性作用。铁调素过表达和铁过载与 COVID-19 感染有关，可被视为潜在的治疗靶点。多项研究表明，达肝素（抗铁调素）可以通过适当调节和减少氧化应激和炎症来改善糖尿病患者 COVID-19 的症状。这一发现可能会加强现有的关于减少糖尿病患者 Covid-19 损伤的治疗措施的知识，并被建议作为一种可能的糖尿病治疗剂。
京公网安备 11010802027423号